Huijun Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huijun Zhu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Xu-Dong Wang
Department of Laboratory Medicine Affiliated Hospital of Nantong University Nantong Jiangsu China
3 shared publications - Jianfei Huang
Department of Clinical Biobank, Affiliated Hospital of Nantong University, Nantong, P.R. China
2 shared publications - Chen-Xia Sun
Traditional Chinese Medicine Department of Rheumatism, Shenzhen Nanshan People's Hospital, Guangdong Shenzhen 518060, China
1 shared publication - Chenyi Wang
School of Information Engineering, Tianjin University of Commerce, Tianjin, China
1 shared publication - Danjing Luo
Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China
1 shared publication - Dawei Zhang
Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 1 November 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 111 (3) , e241
Is the Equivalent Uniform Dose Model Being Used Properly? Impact of Dose Distribution on Parameter and Predictive Ability
- 1 November 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 111 (3) , e241
Open AccessIs the Equivalent Uniform Dose Model Being Used Properly? Impact of Dose Distribution on Parameter and Predictive Ability
- 8 July 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 21 (8) , 734-740
Treatment with Melittin Induces Apoptosis and Autophagy of Fibroblast-like Synoviocytes in Patients with Rheumatoid Arthritis
Background: Melittin, the major medicinal component of honeybee venom, exerts antiinflammatory, analgesic, and anti-arthritic effects in patients with Rheumatoid Arthritis (RA). RA is an inflammatory autoimmune joint disease that leads to irreversible joint destruction and functional loss. Fibroblast-Like Synoviocytes (FLS) are dominant, special mesenchymal cells characterized by the structure of the synovial intima, playing a crucial role in both the initiation and progression of RA. Objective: In this study, we evaluated the effects of melittin on the viability and apoptosis of FLS isolated from patients with RA. Methods: Cell viability was determined using CCK-8 assays; apoptosis was evaluated by flow cytometry, and the expression levels of apoptosis-related proteins (caspase-3, caspase-9, BAX, and Bcl-2) were also determined. To explore whether melittin alters inflammatory processes in RA-FLS, IL-1β levels were determined using an enzyme-linked immunosorbent assay (ELISA). Furthermore, we performed GFP-LC3 punctate fluorescence dot assays and western blotting (for LC3, ATG5, p62, and Beclin 1) to assess autophagy in RA-FLS. Results: Our results show that melittin can significantly impair viability, promote apoptosis and autophagy, and inhibit IL-1β secretion in RA-FLS. Conclusion: Melittin may be useful in preventing damage to the joints during accidental local stimulation.
- 8 July 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 21 (8) , 734-740
Treatment with Melittin Induces Apoptosis and Autophagy of Fibroblast-like Synoviocytes in Patients with Rheumatoid Arthritis
Background: Melittin, the major medicinal component of honeybee venom, exerts antiinflammatory, analgesic, and anti-arthritic effects in patients with Rheumatoid Arthritis (RA). RA is an inflammatory autoimmune joint disease that leads to irreversible joint destruction and functional loss. Fibroblast-Like Synoviocytes (FLS) are dominant, special mesenchymal cells characterized by the structure of the synovial intima, playing a crucial role in both the initiation and progression of RA. Objective: In this study, we evaluated the effects of melittin on the viability and apoptosis of FLS isolated from patients with RA. Methods: Cell viability was determined using CCK-8 assays; apoptosis was evaluated by flow cytometry, and the expression levels of apoptosis-related proteins (caspase-3, caspase-9, BAX, and Bcl-2) were also determined. To explore whether melittin alters inflammatory processes in RA-FLS, IL-1β levels were determined using an enzyme-linked immunosorbent assay (ELISA). Furthermore, we performed GFP-LC3 punctate fluorescence dot assays and western blotting (for LC3, ATG5, p62, and Beclin 1) to assess autophagy in RA-FLS. Results: Our results show that melittin can significantly impair viability, promote apoptosis and autophagy, and inhibit IL-1β secretion in RA-FLS. Conclusion: Melittin may be useful in preventing damage to the joints during accidental local stimulation.
- Open Access
- 15 September 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (45) , 73638-73650
Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer
Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer
- 15 September 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (45) , 73638-73650
Open AccessDecreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer
Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer
- Open Access
- 10 February 2016
- Published by Spandidos Publications in Oncology Letters
- Vol. 11 (4) , 2391-2397
Overexpression of GRO-β is associated with an unfavorable outcome in colorectal cancer
Growth-related oncogene (GRO)-β, or chemokine (C-X-C motif) ligand 2 (CXCL2), is a member of the CXC chemokine family that may mediate various functions, including attracting neutrophils to sites of inflammation, and participating in tumorigenesis and progression. However, the expression of GRO-β in colorectal cancer (CRC) and the association with the clinical outcome of the disease remains poorly understood. In the present study, CXCL2 mRNA expression in CRC was analyzed using six independent datasets from the Oncomine microarray database. The immunohistochemical analysis of tissue microarrays (TMA) was used to characterize the expression of the GRO-β protein in CRC. The association between GRO-β expression and the clinicopathological features and prognosis of patients was determined by statistical analysis. The results indicated that GRO-β was highly expressed in CRC tissues, and that high GRO-β cytoplasmic expression was associated with the tumor location, extent of the primary tumor, and lymph node metastasis. Kaplan-Meier survival and Cox regression analysis revealed that high GRO-β expression was an independent indicator of poor prognosis for CRC patients. The results indicate that high GRO-β expression in CRC may correlate with an unfavorable outcome and facilitate cancer cell invasion and metastasis.
- 10 February 2016
- Published by Spandidos Publications in Oncology Letters
- Vol. 11 (4) , 2391-2397
Open AccessOverexpression of GRO-β is associated with an unfavorable outcome in colorectal cancer
Growth-related oncogene (GRO)-β, or chemokine (C-X-C motif) ligand 2 (CXCL2), is a member of the CXC chemokine family that may mediate various functions, including attracting neutrophils to sites of inflammation, and participating in tumorigenesis and progression. However, the expression of GRO-β in colorectal cancer (CRC) and the association with the clinical outcome of the disease remains poorly understood. In the present study, CXCL2 mRNA expression in CRC was analyzed using six independent datasets from the Oncomine microarray database. The immunohistochemical analysis of tissue microarrays (TMA) was used to characterize the expression of the GRO-β protein in CRC. The association between GRO-β expression and the clinicopathological features and prognosis of patients was determined by statistical analysis. The results indicated that GRO-β was highly expressed in CRC tissues, and that high GRO-β cytoplasmic expression was associated with the tumor location, extent of the primary tumor, and lymph node metastasis. Kaplan-Meier survival and Cox regression analysis revealed that high GRO-β expression was an independent indicator of poor prognosis for CRC patients. The results indicate that high GRO-β expression in CRC may correlate with an unfavorable outcome and facilitate cancer cell invasion and metastasis.
- Open Access
- 1 February 2016
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (8) , e2803
Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer
Kinesin family member 2A (KIF2A) is a member of Kinesin-13 family and involved in cell migration and cell signaling. Human epidermal growth factor receptor 2 (HER2-neu) is implicated in the development of many cancers. Both of these 2 proteins are upstream inducer of PI3K/AKT signaling pathway that plays an important role in the regulation of many cellular events including proliferation, survival, and invasion. We hypothesized that aberrant KIF2A and HER2-neu expression might be associated with aggressive behavior of epithelial ovarian cancer (EOC). To address the prognostic implications of KIF2A and HER2-neu in EOC, we assessed protein levels of KIF2A and HER2-neu in 159 ovarian and fallopian tube tissues (111 carcinomas and 48 normal ovary or fallopian tube tissues) by immunohistochemistry (IHC) analysis on tissue microarray and KIF2A mRNA levels in 35 ovarian and fallopian tube tissues (15 carcinomas and 20 normal ovary or fallopian tube tissues) by real-time PCR. We found that significantly higher KIF2A mRNA expression in EOC tumors than that in normal ovary or fallopian tube tissues. The IHC results showed that protein of KIF2A and HER2-neu was overexpressed in EOC tissues compared with normal ovary or fallopian tube tissues, and KIF2A expression level was significantly associated with lymph nodes, metastasis, ascites cells, and FIGO stage. No correlation between KIF2A and HER2-neu expression was observed. Survival analysis showed that patients with KIF2A and HER2-neu overexpression had a worse overall survival (OS) as compared to patients with low or none expression of the 2 proteins. Multivariate analysis of variance revealed that overexpression of KIF2A was an independent prognostic factor for OS. These findings indicate the important role of KIF2A in predicting EOC prognosis.
- 1 February 2016
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (8) , e2803
Open AccessPrognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer
Kinesin family member 2A (KIF2A) is a member of Kinesin-13 family and involved in cell migration and cell signaling. Human epidermal growth factor receptor 2 (HER2-neu) is implicated in the development of many cancers. Both of these 2 proteins are upstream inducer of PI3K/AKT signaling pathway that plays an important role in the regulation of many cellular events including proliferation, survival, and invasion. We hypothesized that aberrant KIF2A and HER2-neu expression might be associated with aggressive behavior of epithelial ovarian cancer (EOC). To address the prognostic implications of KIF2A and HER2-neu in EOC, we assessed protein levels of KIF2A and HER2-neu in 159 ovarian and fallopian tube tissues (111 carcinomas and 48 normal ovary or fallopian tube tissues) by immunohistochemistry (IHC) analysis on tissue microarray and KIF2A mRNA levels in 35 ovarian and fallopian tube tissues (15 carcinomas and 20 normal ovary or fallopian tube tissues) by real-time PCR. We found that significantly higher KIF2A mRNA expression in EOC tumors than that in normal ovary or fallopian tube tissues. The IHC results showed that protein of KIF2A and HER2-neu was overexpressed in EOC tissues compared with normal ovary or fallopian tube tissues, and KIF2A expression level was significantly associated with lymph nodes, metastasis, ascites cells, and FIGO stage. No correlation between KIF2A and HER2-neu expression was observed. Survival analysis showed that patients with KIF2A and HER2-neu overexpression had a worse overall survival (OS) as compared to patients with low or none expression of the 2 proteins. Multivariate analysis of variance revealed that overexpression of KIF2A was an independent prognostic factor for OS. These findings indicate the important role of KIF2A in predicting EOC prognosis.
- 31 December 2014
- Published by Taylor & Francis in Instrumentation Science & Technology
- Vol. 43 (1) , 53-64
Determination of Metalaxyl in Potatoes and Soil by Dispersive Solid-Phase Extraction and High-Performance Liquid Chromatography
A simple and sensitive high-performance liquid chromatography method with photodiode array detection combined with dispersive solid-phase extraction was developed to quantify metalaxyl residues in potatoes and soil. The limits of detection and quantification of metalaxyl were 0.0015 and 0.005 mg kg−1. The recoveries of metalaxyl extracted from potato, potato foliage, and soil ranged from 81.53–95.50%, 90.12–94.72%, 93.16–103.0%, respectively, with relative standard deviations less than 9.74%. The method was applied to determine metalaxyl in potatoes and soil; the results showed that the dissipation rates were described by first-order kinetics. The half-lives in potato foliage and soil were 0.75 days and 5.87 days to 8.45 days, respectively. At harvest, the residue of metalaxyl in potatoes was less than 0.05 mg kg−1 following the recommended dosage at an interval of seven days from the final application. These results may be used to help establish appropriate application frequencies and harvest intervals for metalaxyl on potatoes.
- 31 December 2014
- Published by Taylor & Francis in Instrumentation Science & Technology
- Vol. 43 (1) , 53-64
Determination of Metalaxyl in Potatoes and Soil by Dispersive Solid-Phase Extraction and High-Performance Liquid Chromatography
A simple and sensitive high-performance liquid chromatography method with photodiode array detection combined with dispersive solid-phase extraction was developed to quantify metalaxyl residues in potatoes and soil. The limits of detection and quantification of metalaxyl were 0.0015 and 0.005 mg kg−1. The recoveries of metalaxyl extracted from potato, potato foliage, and soil ranged from 81.53–95.50%, 90.12–94.72%, 93.16–103.0%, respectively, with relative standard deviations less than 9.74%. The method was applied to determine metalaxyl in potatoes and soil; the results showed that the dissipation rates were described by first-order kinetics. The half-lives in potato foliage and soil were 0.75 days and 5.87 days to 8.45 days, respectively. At harvest, the residue of metalaxyl in potatoes was less than 0.05 mg kg−1 following the recommended dosage at an interval of seven days from the final application. These results may be used to help establish appropriate application frequencies and harvest intervals for metalaxyl on potatoes.